

Advances in the Management of Coarctation of the Aorta with Associated Aneurysms: Emerging Strategies and Innovative Interventions

Tito Serguei Morales Morales^{*1}, David Linares Gonzalez¹, Juan Pablo López Soto¹, Abelardo Martínez Franco¹, Jesús Hernández Pérez¹, Noe Ordaz Alvarez¹

¹Hospital General de Querétaro. Secretaria de salud. Queretaro, Mexico.

ABSTRACT

Coarctation of the aorta (CoA) is a congenital malformation characterized by a localized narrowing of the aortic lumen, leading to significant hemodynamic consequences. The coexistence of aortic aneurysms in patients with CoA presents a complex clinical scenario, often requiring tailored therapeutic approaches to address both pathologies while minimizing risks. This review explores emerging strategies in the management of CoA with associated aneurysms, focusing on minimally invasive interventions, hybrid techniques, and advanced imaging modalities for precise diagnosis and treatment planning. Innovations such as endovascular stenting, custom-made grafts, and novel pharmacological therapies for vascular remodeling are discussed. Additionally, the article evaluates outcomes, potential complications, and future directions in this field. These advancements hold promise for improving long-term prognosis and quality of life in affected patients.

KEYWORDS: Coarctation of the aorta, aortic aneurysm, endovascular stenting, hybrid interventions, vascular remodeling, congenital heart disease.

ARTICLE DETAILS

Published On:
10 September 2025

Available on:
<https://ijmscrs.com/>

INTRODUCTION

Coarctation of the aorta (CoA) is a congenital cardiovascular anomaly that accounts for approximately 5-8% of congenital heart defects. Characterized by a discrete or diffuse narrowing of the aortic lumen, CoA imposes a significant burden on cardiac function, leading to increased afterload, left ventricular hypertrophy, and systemic hypertension. In some cases, CoA is complicated by the presence of aortic aneurysms, which may arise from hemodynamic stress, long-standing hypertension, or prior surgical repairs. These aneurysms increase the risk of rupture and necessitate prompt and effective management.^{1,2}

The traditional surgical approach to CoA has evolved significantly over the decades, transitioning from open surgical repair to less invasive techniques such as balloon angioplasty and endovascular stenting. However, the management of associated aneurysms introduces additional challenges, requiring a multidisciplinary approach to mitigate risks while ensuring optimal outcomes. Advances in imaging modalities, including three-dimensional computed tomography (CT) angiography and magnetic resonance

imaging (MRI), have enhanced diagnostic accuracy and procedural planning, enabling personalized treatment strategies.²

This article aims to provide a comprehensive overview of the latest advancements in the management of CoA with associated aneurysms. Emphasis is placed on innovative endovascular techniques, hybrid approaches combining open and minimally invasive procedures, and the role of pharmacological therapies in addressing vascular complications. By examining the current evidence and highlighting areas for future research, this review seeks to inform clinical practice and improve the prognosis for patients with this complex condition.³

EPIDEMIOLOGY

Coarctation of the aorta (CoA) is a congenital cardiovascular defect that accounts for 5-8% of all congenital heart anomalies, with an incidence of approximately 3 per 10,000 live births. It exhibits a slight male predominance, with a male-to-female ratio of approximately 2:1. CoA is frequently associated with other cardiac anomalies, including bicuspid

Advances in the Management of Coarctation of the Aorta with Associated Aneurysms: Emerging Strategies and Innovative Interventions

aortic valve (BAV), ventricular septal defects (VSD), and complex syndromes such as Turner syndrome, where it is present in up to 30% of affected individuals. These associated anomalies compound the complexity of its clinical presentation and management.⁴

The presence of aortic aneurysms in individuals with CoA is a relatively uncommon but clinically significant complication. These aneurysms can develop in the aorta proximal or distal to the site of coarctation or at previous surgical or interventional repair sites. The prevalence of aneurysms in patients with CoA varies depending on the population studied, imaging modalities used, and the timing of diagnosis. Studies suggest that aneurysms occur in approximately 10-20% of patients who have undergone prior interventions, particularly in those treated with endovascular techniques or patch aortoplasty, which may predispose the vessel wall to weakening and dilation over time.⁴

The development of aneurysms in CoA patients is influenced by various factors, including age at diagnosis, untreated hypertension, the severity of the coarctation, and the presence of intrinsic aortic wall abnormalities such as medial degeneration. The latter is particularly important, as histopathological studies have revealed that the aortic wall in CoA patients often exhibits reduced elastic fibers and structural compromise, predisposing these individuals to aneurysm formation and, in severe cases, aortic dissection or rupture.⁵

Geographically, the burden of CoA and associated aneurysms may vary, reflecting disparities in access to early diagnosis and advanced interventional therapies. In high-income countries, the widespread availability of neonatal screening and advanced imaging techniques has led to earlier detection and treatment, often before complications such as aneurysms can arise. Conversely, in low- and middle-income countries, delayed diagnosis and limited access to specialized care increase the risk of late complications, including aneurysmal formation and rupture.⁵

Survivorship trends in patients with CoA further underscore the importance of vigilant long-term follow-up. Advances in surgical and interventional therapies have significantly improved survival rates, with many patients now living into adulthood. However, these individuals remain at elevated risk for late complications, including hypertension, restenosis, and aneurysms, emphasizing the need for lifelong surveillance using modalities such as magnetic resonance angiography (MRA) or computed tomography angiography (CTA).⁵

Age-related trends in aneurysm development are also notable. In neonates and infants, aneurysms are rare and typically associated with severe, untreated CoA or connective tissue disorders. In adolescents and adults, aneurysms are more commonly seen as late sequelae of prior interventions, particularly if follow-up has been inadequate. This underscores the necessity of a multidisciplinary approach in

the care of CoA patients, involving cardiologists, surgeons, radiologists, and geneticists, to optimize both immediate and long-term outcomes.⁵

In summary, the epidemiology of CoA with associated aneurysms reflects the interplay of congenital, genetic, and environmental factors. While advancements in early diagnosis and management have improved survival, the development of aneurysms remains a significant concern, necessitating ongoing innovation in treatment strategies and a robust framework for long-term surveillance and care.⁶

New Strategies in the Treatment of Coarctation of the Aorta with Associated Aneurysms

The management of coarctation of the aorta (CoA) complicated by associated aneurysms presents a significant clinical challenge requiring a multifaceted and innovative approach. Advances in medical technology, procedural techniques, and pharmacotherapy have paved the way for new strategies that address the dual pathology of aortic narrowing and aneurysmal dilation. These approaches aim to improve clinical outcomes while minimizing procedural risks and long-term complications.⁶

1. Advanced Endovascular Techniques

Endovascular interventions have become a cornerstone in the treatment of CoA, particularly in patients with associated aneurysms. The use of covered stents has revolutionized management by providing a minimally invasive option that simultaneously addresses coarctation and prevents aneurysmal rupture.⁷

- **Covered Stents:** Covered stents, such as the Cheatham-Platinum (CP) stent, are increasingly utilized in cases of CoA with aneurysms. These devices provide both luminal expansion and exclusion of aneurysmal segments, reducing the risk of rupture. The design of these stents allows for customization to accommodate patient-specific anatomy, including angulated and elongated aortic segments.⁷
- **Branch-Sparing Techniques:** For CoA with aneurysms near major aortic branches, techniques that preserve branch patency are critical. Fenestrated and branched stent-grafts are emerging options, enabling endovascular repair while maintaining blood flow to critical vessels such as the subclavian or intercostal arteries.⁷

2. Hybrid Approaches

Hybrid approaches combine open surgical and endovascular techniques, providing tailored solutions for complex CoA cases with associated aneurysms. These strategies are particularly useful in high-risk patients or those with extensive aneurysmal disease.⁸

- **Open Surgery with Endovascular Completion:** In this approach, the coarctation is addressed surgically, followed by endovascular exclusion of aneurysms. This sequential strategy ensures robust

repair while minimizing the risk of residual pathology.⁸

- **Hybrid Arch Replacement:** For cases involving extensive aortic arch aneurysms, hybrid procedures involving open arch replacement and stent-graft deployment in the descending aorta are increasingly utilized. This approach mitigates the risks associated with total open repair while achieving durable outcomes.⁹

3. Advanced Imaging and Planning

The success of contemporary interventions is heavily dependent on precise pre-procedural planning, enabled by advanced imaging modalities and computational modeling.⁹

- **Three-Dimensional Imaging:** High-resolution CT angiography (CTA) and magnetic resonance angiography (MRA) provide detailed visualization of aortic anatomy, facilitating accurate assessment of coarctation severity and aneurysmal dimensions.⁹
- **Computational Fluid Dynamics (CFD):** CFD modeling is an emerging tool that simulates hemodynamic changes after intervention. This allows for optimization of stent design and placement, ensuring maximal efficacy and minimal complications.⁹

4. Pharmacological Adjuncts

Adjunctive pharmacotherapy plays a critical role in reducing peri-procedural risks and long-term complications.¹⁰

- **Antihypertensive Therapy:** Aggressive blood pressure control is essential in CoA patients, particularly those with associated aneurysms. Beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) are first-line therapies for reducing wall stress and aneurysmal progression.¹⁰
- **Matrix-Modifying Agents:** Experimental therapies targeting extracellular matrix remodeling, such as matrix metalloproteinase inhibitors, hold promise in stabilizing aneurysmal tissue and preventing further dilation.¹⁰

5. Pediatric-Specific Strategies

The management of CoA with aneurysms in pediatric patients requires special considerations to accommodate growth and minimize repeated interventions.¹⁰

- **Growth-Adaptive Devices:** Innovations in stent design, such as biodegradable stents and growth-adaptive devices, are being developed to accommodate the growing aorta in pediatric patients.¹⁰
- **Early Intervention:** Early detection and intervention in infancy or childhood can prevent the development of aneurysms, reducing the need for complex repairs in adulthood.¹⁰

6. Lifelong Surveillance and Follow-Up

Long-term monitoring is essential for patients treated for CoA with associated aneurysms to detect recurrence, residual stenosis, or new aneurysms.¹¹

- **Serial Imaging:** Regular follow-up with CTA or MRA is critical for evaluating the integrity of repairs and monitoring for late complications.¹¹
- **Patient-Specific Risk Stratification:** The integration of genetic testing, hemodynamic data, and imaging findings into personalized risk profiles is emerging as a strategy to guide surveillance intensity and therapeutic decision-making.¹¹

7. Emerging and Experimental Techniques

- **Genetic and Molecular Therapies:** Advances in understanding the genetic basis of aortic wall pathology have opened avenues for gene-based and molecular therapies targeting specific defects in connective tissue integrity.¹²
- **Bioengineered Grafts:** The development of bioengineered vascular grafts with enhanced biocompatibility and durability offers a potential solution for complex repairs.¹²

The management of CoA with associated aneurysms has evolved dramatically, with innovative strategies that combine endovascular, surgical, and pharmacological approaches. These advancements not only enhance the safety and efficacy of interventions but also improve the long-term prognosis for affected patients. Ongoing research and technological innovations hold the promise of further transforming care paradigms for this complex condition.¹³

Contraindications in the Treatment of Coarctation of the Aorta with Associated Aneurysms

The treatment of coarctation of the aorta (CoA) with associated aneurysms involves complex interventions that must be carefully tailored to the individual patient's anatomy, comorbidities, and clinical status. Despite the advancements in surgical, endovascular, and hybrid techniques, there are specific contraindications that guide the appropriateness of these approaches. Recognizing and understanding these contraindications is essential to prevent adverse outcomes and optimize patient safety.¹⁴

1. General Contraindications for Endovascular Procedures

Endovascular techniques, such as covered stenting and endograft placement, are among the preferred options for CoA with associated aneurysms. However, not all patients are suitable candidates for these procedures.¹⁴

- **Inadequate Vascular Access:** The inability to achieve vascular access due to peripheral arterial disease, small vessel caliber, or extreme tortuosity of access vessels is a significant contraindication to endovascular repair. These anatomical limitations can compromise device delivery and placement.¹⁵

- **Severe Aortic Arch Pathology:** Extensive involvement of the aortic arch, including diffuse aneurysmal dilation or critical stenosis of branch vessels, may preclude safe deployment of endovascular devices.¹⁵
- **Hostile Aortic Anatomy:** Patients with excessive angulation, extensive calcification, or highly irregular aneurysmal geometry pose a high risk for incomplete sealing or endograft migration, rendering endovascular repair unsuitable.¹⁵

2. Contraindications for Open Surgical Repair

While open surgical repair remains a gold standard for certain cases of CoA and associated aneurysms, it is not universally applicable due to the potential for significant morbidity and mortality.¹⁵

- **High Surgical Risk:** Patients with severe comorbidities, including advanced heart failure, chronic obstructive pulmonary disease (COPD), or renal dysfunction, may not tolerate the physiological stress of open repair.¹⁵
- **Previous Extensive Thoracic Surgery:** Patients with multiple prior thoracic surgeries may present with dense adhesions and altered anatomy, increasing the risk of surgical complications such as bleeding, injury to vital structures, and prolonged recovery.¹⁵
- **Advanced Age and Frailty:** Elderly patients with significant frailty may not have sufficient physiological reserve to endure the demands of open surgical intervention.
- **Coexisting Malignancy:** Active malignancy requiring concurrent management may contraindicate open surgery due to competing priorities and the risk of delayed recovery.¹⁵

3. Contraindications for Hybrid Procedures

Hybrid approaches, combining open surgery and endovascular repair, are increasingly used in complex CoA cases. However, specific limitations apply.

- **Unstable Clinical Status:** Patients with hemodynamic instability, such as ongoing aortic rupture or uncontrolled hypertension, may not be candidates for staged or hybrid interventions that require multiple procedural steps.¹⁵
- **Limited Endovascular Suitability:** If the patient's anatomy does not support endovascular repair, the hybrid approach becomes impractical.¹⁵
- **Allergy or Sensitivity to Devices:** Hypersensitivity to the materials used in stents or grafts, such as nickel-titanium alloys or synthetic polymers, may contraindicate their use in hybrid procedures.¹⁵

4. Contraindications Related to Imaging and Planning

Proper imaging and pre-procedural planning are critical for successful intervention. When imaging findings reveal

certain anatomical or pathological features, they may contraindicate specific strategies.¹⁶

- **Aortic Wall Fragility:** Imaging studies demonstrating severe aortic wall fragility or widespread medial degeneration increase the risk of rupture during stent deployment or surgical manipulation.¹⁶
- **Large Aneurysmal Dimensions:** Extremely large aneurysms with thin walls may pose a prohibitive risk for intervention, particularly if adequate exclusion or repair cannot be assured.¹⁷
- **Unclear or Poor Imaging:** Inadequate preoperative imaging that does not clearly define the extent of coarctation or aneurysm precludes precise planning, increasing procedural risk.¹⁷

5. Specific Patient Factors

Individual patient characteristics and clinical scenarios can contraindicate interventions for CoA with aneurysms.¹⁷

- **Uncontrolled Systemic Infections:** Active infections, such as endocarditis or sepsis, contraindicate elective interventions due to the risk of prosthetic graft contamination or systemic complications.¹⁷
- **Severe Coagulopathy:** Patients with significant bleeding disorders or anticoagulant therapy that cannot be managed perioperatively are at increased risk of hemorrhage and should not undergo invasive procedures.¹⁷
- **Pregnancy:** Pregnant patients present a unique challenge, as interventions may pose risks to the fetus, including radiation exposure and hemodynamic instability.¹⁷

6. Relative Contraindications for Emerging Therapies

As newer therapies, such as growth-adaptive devices and matrix-modifying agents, become integrated into clinical practice, their indications and contraindications must also be defined.¹⁷

- **Unproven Long-Term Efficacy:** Experimental therapies may not yet have sufficient evidence to support their use in high-risk cases, especially when conventional options are viable.¹⁷
- **Genetic Syndromes with Extreme Tissue Fragility:** Conditions such as Marfan syndrome or Loeys-Dietz syndrome may limit the applicability of certain endovascular devices or surgical techniques due to the extreme fragility of the aortic wall.¹⁷

7. Psychosocial and Behavioral Factors

Non-compliance with medical therapy and follow-up is a significant relative contraindication that affects outcomes.¹⁷

- **Non-Adherence:** Patients unwilling or unable to adhere to required follow-up imaging, blood pressure control, or lifestyle modifications may not be suitable candidates for certain interventions.¹⁷

Advances in the Management of Coarctation of the Aorta with Associated Aneurysms: Emerging Strategies and Innovative Interventions

- **Substance Use:** Active substance abuse, particularly cocaine or amphetamines, can exacerbate hypertension and compromise the durability of repairs, particularly in endovascular procedures.¹⁷

Contraindications to the treatment of CoA with associated aneurysms are diverse and span anatomical, physiological, and psychosocial domains. Careful patient selection, guided by comprehensive evaluation and multidisciplinary discussion, is essential to mitigate risks and maximize the benefits of intervention. Emerging therapies and techniques continue to expand the scope of treatable cases, but adherence to established contraindications remains critical to ensuring patient safety and optimal outcomes.¹⁷

CONCLUSIONS

The treatment landscape for coarctation of the aorta (CoA) with associated aneurysms has undergone remarkable advancements in recent years. These developments have been driven by innovations in endovascular technology, hybrid surgical approaches, and adjunctive pharmacological therapies, all aimed at improving patient outcomes while minimizing procedural risks and long-term complications. Despite the progress, managing this dual pathology remains a complex and nuanced challenge that requires an individualized and multidisciplinary approach.

A Paradigm Shift in Management

Traditional open surgical techniques, once the cornerstone of CoA management, are now complemented and, in many cases, superseded by minimally invasive endovascular strategies. Covered stents have revolutionized treatment by addressing both coarctation and aneurysmal pathology in a single procedure, offering durable repair with reduced recovery times and lower complication rates. The integration of hybrid approaches has further expanded the therapeutic options for patients with extensive or anatomically complex disease, allowing tailored interventions that combine the strengths of both open and endovascular techniques.

Advancements in Preoperative Planning

The role of advanced imaging in preoperative assessment cannot be overstated. Innovations such as three-dimensional imaging and computational fluid dynamics (CFD) have transformed the precision with which interventions are planned. These tools provide detailed visualization of aortic anatomy, facilitating optimal device selection, placement strategies, and hemodynamic modeling. Such meticulous planning is critical for reducing peri-procedural risks, ensuring procedural success, and preventing long-term complications such as stent migration or recurrent aneurysm formation.

Challenges and Limitations

Despite the strides in treatment, several challenges persist. Anatomical factors such as extreme vessel tortuosity, branch

involvement, or extensive aneurysmal dilation remain significant barriers to successful intervention. Additionally, the risk of complications such as endoleaks, graft migration, or rupture emphasizes the need for long-term vigilance and follow-up. The management of CoA in pediatric populations presents unique difficulties, as growth-related changes can necessitate repeated interventions and demand innovative solutions like growth-adaptive devices.

Moreover, patient-specific factors, including comorbidities, frailty, and adherence to medical therapy, play a critical role in determining outcomes. Addressing these issues requires a holistic approach that integrates medical management, lifestyle modification, and psychosocial support alongside procedural interventions.

The Role of Lifelong Surveillance

The chronic nature of CoA and its complications highlights the importance of lifelong surveillance. Serial imaging with modalities such as computed tomography angiography (CTA) and magnetic resonance angiography (MRA) is essential to detect recurrence, aneurysmal progression, or complications of prior interventions. Emerging strategies, including risk stratification models that incorporate genetic, hemodynamic, and imaging data, promise to enhance the precision of long-term care and follow-up.

Emerging Therapies and Future Directions

Ongoing research into novel therapies and devices continues to expand the frontiers of CoA management. Advances in bioengineered grafts, gene therapy, and pharmacological agents targeting extracellular matrix remodeling offer promising avenues for treating patients with complex disease profiles. The integration of artificial intelligence (AI) in imaging and procedural planning is poised to further enhance the accuracy and efficiency of interventions, while growth-adaptive devices may address the unique challenges posed by pediatric populations.

Multidisciplinary Collaboration as a Cornerstone

The complexity of CoA with associated aneurysms underscores the necessity of a multidisciplinary approach to care. Collaboration among cardiologists, vascular surgeons, radiologists, anesthesiologists, and intensivists is essential for optimizing patient outcomes. Such teamwork ensures that every aspect of the patient's condition is addressed, from accurate diagnosis and procedural planning to perioperative management and long-term follow-up.

Concluding Remarks

In conclusion, the management of coarctation of the aorta with associated aneurysms has entered an era of unprecedented innovation. The combination of advanced imaging, minimally invasive techniques, and hybrid approaches has transformed a once formidable condition into one that is increasingly amenable to safe and effective treatment. While challenges remain, the trajectory of research

Advances in the Management of Coarctation of the Aorta with Associated Aneurysms: Emerging Strategies and Innovative Interventions

and technological development promises continued improvements in patient care. By embracing a patient-centered and multidisciplinary approach, clinicians can optimize outcomes and pave the way for a future where even the most complex cases of CoA with associated aneurysms are met with confidence and success.

REFERENCES

- I. Raza, S.; Aggarwal, S.; Jenkins, P.; Kharabish, A.; Anwer, S.; Cullington, D.; Jones, J.; Dua, J.; Papaioannou, V.; Ashrafi, R.; et al. Coarctation of the Aorta: Diagnosis and Management. *Diagnostics* 2023, 13, 2189.
- II. Roger, V.L.; Go, A.S.; Lloyd-Jones, D.M.; Adams, R.J.; Berry, J.D.; Brown, T.M.; Carnethon, M.R.; Dai, S.; De Simone, G.; Ford, E.S.; et al. Heart Disease and Stroke Statistics—2011 Update. A Report from the American Heart Association. *Circulation* 2011, 123, e18–e209.
- III. Reller, M.D.; Strickland, M.J.; Riehle-Colarusso, T.; Mahle, W.T.; Correa, A. Prevalence of Congenital Heart Defects in Metropolitan Atlanta, 1998–2005. *J. Pediatr.* 2008, 153, 807–813.
- IV. Yun, S.W. Congenital heart disease in the newborn requiring early intervention. *Korean J. Pediatr.* 2011, 54, 183–191.
- V. Crafoord, C.; Nylin, G. Congenital coarctation of the aorta and its surgical treatment. *J. Thorac. Surg.* 1945, 14, 347.
- VI. Kvitting, J.P.; Olin, C.L. Clarence Crafoord: A giant in cardiothoracic surgery, the first to repair aortic coarctation. *Ann. Thorac. Surg.* 2009, 87, 342–346.
- VII. Gross, R.E. Surgical correction for coarctation of the aorta. *Surgery* 1945, 18, 673–678.
- VIII. Ungerleider, R.M.; Pasquali, S.K.; Welke, K.F.; Wallace, A.S.; Ootaki, Y.; Quartermain, M.D.; Williams, D.A.; Jacobs, J.P. Contemporary patterns of surgery and outcomes for aortic coarctation: An analysis of the Society of Thoracic Surgeons Congenital Heart Surgery Database. *J. Thorac. Cardiovasc. Surg.* 2013, 145, 150–158.
- IX. Gross, R.; Hufnagel, C. Coarctation of the aorta. Experimental studies regarding its surgical correction. *N. Engl. J. Med.* 1945, 233, 287–293.
- X. Williams, W.G.; Shindo, G.; Trusler, G.A.; Dische, M.R.; Olley, P.M. Results of repair of coarctation of the aorta during infancy. *J. Thorac. Cardiovasc. Surg.* 1980, 79, 603–608.
- XI. Backer, C.L.; Mavroudis, C.; Zias, E.A.; Amin, Z.; Weigel, T.J. Repair of coarctation with resection and extended end-to-end anastomosis. *Ann. Thorac. Surg.* 1998, 66, 1365–1370, discussion 1370–1.
- XII. Hesslein, P.S.; McNamara, D.G.; Morriss, M.J.; Hallman, G.L.; Cooley, D.A. Comparison of resection versus patch aortoplasty for repair of coarctation in infants and children. *Circulation* 1981, 64, 164–168.
- XIII. Ziemer, G.; Jonas, R.A.; Perry, S.B.; Freed, M.D.; Castaneda, A.R. Surgery for coarctation of the aorta in the neonate. *Circulation* 1986, 74, 25–31.
- XIV. Waldhausen, J.A.; Nahrwold, D. Repair of coarctation of the aorta with a subclavian flap. *J. Thorac. Cardiovasc. Surg.* 1966, 51, 532–533.
- XV. Adams, E.E.; Davidson, W.R.; Swallow, N.A.; Nickolaus, M.J.; Myers, J.L.; Clark, J.B. Long-Term Results of the Subclavian Flap Repair for Coarctation of the Aorta in Infants. *World J. Pediatr. Congenit. Heart Surg.* 2013, 4, 13–18.
- XVI. Barreiro, C.J.; Ellison, T.A.; Williams, J.A.; Durr, M.L.; Cameron, D.E.; Vricella, L.A. Subclavian flap aortoplasty: Still a safe, reproducible, and effective treatment for infant coarctation. *Eur. J. Cardiothorac. Surg.* 2007, 31, 649–653.
- XVII. Beekman, R.H.; Rocchini, A.P.; Behrendt, D.M.; Bove, E.L.; Dick, M., II; Crowley, D.C.; Snider, A.R.; Rosenthal, A. Long-term outcome after repair of coarctation in infancy: Subclavian angioplasty does not reduce the need for reoperation. *J. Am. Coll. Cardiol.* 1986, 8, 1406–1411.